Skip to main content
. 2022 Feb 25;3(3):100534. doi: 10.1016/j.xcrm.2022.100534

Figure 6.

Figure 6

Tumor lysate-based therapeutic vaccination against T cell lymphoma

(A) Schematic representation of the timeline used for allogeneic therapeutic vaccination.

(B and C) Assessment of tumor growth volume (B) and survival (C) of animals challenged with the EL4 tumor following Balb/c-derived allogeneic mature DCs pulsed with EL4 lysate/EL4-Accum-lysate. Ctl mice are shown in black, anti-PD-1 in dotted black, DC/EL4 lysate in green, DC-EL4 Accum-lysate in blue, DC/EL4 lysate + anti-PD-1 in purple, and DC/EL4 Accum-lysate + anti-PD-1 in red.

(D) Schematic representation of the experimental design of the TILs study.

(E) Analysis of various immune cells in tumors derived from all groups shown in (B and C).

(F) Absolute number of Tregs/gram of tumor from all groups shown in (B and C).

(G) Assessment of the CD8/Treg ratio in the tumors depicted in (B and C). For (B and C), n = 10/group. For (E–G), n = 5/group with ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. See also Figures S7 and S8.